Why I’d buy this hot growth stock over Provident Financial plc

As Provident Financial plc (LON: PFG) struggles, I like the look of this growth stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Trying to catch falling knives is a risky sport. Even though you can make an impressive return if you pick the right stock, more often than not the turnaround story flames out, and you end up burning your fingers. As Warren Buffett once said, “turnarounds seldom turn.

After a disastrous decision to try and turn its part-time employees into full-time workers, Provident Financial (LSE: PFG). Fell into the turnaround bucket. By changing its employment structure, management was trying to cut costs, but this has failed spectacularly.

Following the changes, employees fled the doorstep lender and losses started to pile up. Only 57% of the firm’s outstanding debts were collected in August (a figure that’s since recovered to 65%) and overall this year, management is projecting losses from debt write-offs of £120m. 

Time to catch the knife?

Even though some analysts are positive about the outlook for Provident, including my Foolish colleague Peter Stephens, I’m not so sure. You see, the company’s problems have resulted in its best agents, which have the best customers, moving to rivals, taking business with them, and it’s going to be hard to win back these customers

Even though City analysts are predicting a recovery in the company’s earnings next year (up 64% to 91p), they’re still projected to come in at around half the level reported for 2016 (178p). Analysts are also predicting a dividend of 31p per share, down around 77% since 2016. 

A better buy 

As Provident struggles, I prefer the look of Polypipe (LSE: PLP). Unlike the doorstep lender, this one is still growing strongly in a defensive industry. Indeed, today the company announced that it is on track to meet full-year guidance after a “strong” performance in the first 10 months of the year. For period ended October 31, revenue expanded 8.1% to £400.6m. On a like-for-like basis, revenue grew 7.1%. Revenue growth was driven by robust UK Residential Systems growth of 9.9% to £193m. 

In mainland Europe, revenue for the period expanded 19.9% or 11.2% on a like-for-like basis. CEO Martin Payne said: “The group continues to deliver strong organic growth ahead of the overall UK construction market, demonstrating the resilience of its balanced exposure to the different sectors within that market, and the continued success of its strategic growth pillars of legacy material substitution and legislative tailwinds in water management and carbon efficiency.”

For the full-year, City analysts expect the company to produce earnings per share growth of 7%, followed by an increase of 8% for 2018. If the company hits these targets, it will have grown earnings per share three-fold in six years. And growth should accelerate in the years ahead as the company pays down its debt, which is currently equal to 2 times EBITDA. Debt is projected to reduce significantly during the second half due to the timing of cash flows. 

As well as paying down debt, management is returning cash to shareholders. The stock currently yields 2.8% and trades at a forward P/E of 14.7. 

So overall, if you’re looking for an income and growth buy, with the potential for further growth as its balance sheet improves, I believe Polypipe could be a great buy. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »